Report updated ALLO-501 and initial ALLO-501A data in relapsed/refractory NHL
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Additional data from the Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL) and initial data from the Phase 1 ALPHA2 study of ALLO-501A are planned for Q2 2021.”
What we found
Evidence strength A What the grades mean
A later 10-Q says updated ALPHA data and initial ALPHA2 data were reported in May 2021, within the Q2 2021 deadline.
-
A Allogene Therapeutics, Inc. 8-K filed 2021-08-04
“Updated data from the ongoing Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory non-Hodgkin lymphoma (NHL) presented at the Company's CD19 Forum in May and Annual Meeting of the American Society of Clinical Oncology (ASCO) in June.” ✓ confirmed on the page
-
A Allogene Therapeutics, Inc. 10-Q filed 2021-08-04
“We reported updated data from the ALPHA trial and initial data from the ALPHA2 trial in May 2021, and expect to report additional data in late 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Updated ALLO-501 and initial ALLO-501A clinical data in NHL
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Allogene Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALLO-024718 · Corrections policy